Precision cancer drugs work, but cost questions loom for lung cancer treatment

A new global analysis confirms that precision medicine—tailored treatments based on tumor genetics—delivers real benefits for non-small cell lung cancer patients. The findings matter for healthcare systems and insurers deciding whether to cover these often-expensive therapies as standard care.

Originaltitel: A global analysis of the value of precision medicine in oncology - The case of non-small cell lung cancer